EURACTIV - Europe's new heart checks could be integrated into Belgian GP care, but the plan still needs federal and regional approval, says president of Belgian Society of Cardiology. Read more

EU PERSPECTIVES - Two new laws promise Europe fewer empty pharmacy shelves and less reliance on foreign drug suppliers. Its own health lawmakers now say the money to deliver on that promise simply is not there. They are demanding 15 per cent more before EU4Health disappears for good. Read more

EU PERSPECTIVES - COVID-19 taught the world one lesson: when the next pandemic hits, the rich will get the vaccines first. More than a year after signing its pandemic treaty, the WHO still cannot fix that problem. The EU's own negotiator says a solution is not coming for months. Read more

EURACTIV - The first disease-modifying treatments have reached Europe, a next generation of drugs, delivery methods and blood tests is already in clinical trials. Read more

EURACTIV - Getting respiratory care right could help patients, ease hospital pressure and cut emissions all at once – but Europe still lacks a plan to make it happen. Read more

EURACTIV - AstraZeneca's clinical trials have been scaling back in Belgium, with the number of studies run by the company falling by around 20%, according to Angela Thompson, country president of AZ for Belgium and Luxembourg. Read more

EURACTIV - Getting respiratory care right could help patients, ease hospital pressure and cut emissions all at once – but Europe still lacks a plan to make it happen. Read more

EU PERSPECTIVES - Fall ill on holiday in another EU country, and the bill is yours to pay first. Patients then wait an average of 69 days to get their money back from home. Lawmakers now want member states to settle up between themselves instead, so patients never have to pay at all. Read more

EURACTIV - UCB is the only company headquartered in the European Union among the nine drugmakers that signed Donald Trump's most-favoured-nation pricing plan on Monday, 31 August. Its new US factory will not come at Europe's expense, the Brussels-based company said. Read more

EU PERSPECTIVES - It can save young lives but it is not attractive enough for investors. That is the cruel economics of childhood cancer treatment. Léonor, a ten-year-old cancer survivor, asks Europe to change that. Read more